NCT06500702: A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- State
- Under way
- Phase
- Phase 2
- People
- 84 planned
- Started
- 19 Dec 2024
- Primary completion
- 23 Dec 2026
- Arms
- Rilzabrutinib
- Results
- None posted
- 15 Jul 2024: Trial registered
- 19 Dec 2024: Trial started